Navigation Links
LSUHSC researcher awarded NCI grant to study link between chronic inflammation and cancer
Date:7/18/2013

New Orleans, LA Yan Cui, PhD, Associate Professor of Microbiology, Immunology, & Parasitology at LSU Health Sciences Center New Orleans and the LSUHSC Stanley S. Scott Cancer Center, has been awarded a $1.5 million grant over five years by the National Cancer Institute to study the role of chronic inflammation in the development and progression of cancer.

Tumor suppressor protein 53, or p53, is a crucial molecule that is known to prevent cancer by either directly killing cancer cells or by stopping cancer cells from multiplying. The loss of p53 function resulting from genetic changes is detected in 50% of tumors and is considered to be one of the leading causes of cancer. However, p53 dysfunction caused by these mutations can also occur in normal cells surrounding the cancer cells, called stromal cells, and mutations in the p53 gene in some of them are associated with increased cancer spread and poor prognosis. According to the National Cancer Institute, a stromal cell is a type of cell that makes up certain types of connective tissue (supporting tissue that surrounds other tissues and organs). When cells become malignant, the surrounding stromal cells also change. So far, it is not entirely clear how these adjacent, normal cells that lack functional p53 affect the growth and replication of cancer cells.

This grant award is based upon published studies performed in Dr. Cui's laboratory, one of which was chronicled as a cover story in the March 15, 2013, issue of Cancer Research.

These studies demonstrated that a lack of functional p53 in tumor-associated stromal cells, as well as some of the immune cells, leads to an inflammatory microenvironment that suppresses the body's immune system to fight the cancer, increases the number of stromal cells infiltrating the tumor, and promotes blood vessel formation to nourish the tumor leading to its accelerated growth.

"These earlier findings broaden our understanding of the im
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. LSUHSC research identifies new risk factors for parasitic infection
2. LSUHSC research discovers new drug target for metastatic breast cancer
3. LSUHSC research identifies co-factors critical to PTSD development
4. LSUHSC scientist awarded nearly $2 million to determine role of biofilms in common fungal infection
5. LSUHSC research discovery provides therapeutic target for ALS
6. LSUHSCs Weiss chosen to help set national eye policy, research
7. LSUHSC research identifies new therapeutic target for Alzheimers disease
8. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
9. LSUHSC research finds treating stress prevented new MS brain lesions
10. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
11. Solving DNA puzzles is overwhelming computer systems, researchers warn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... harness the energy of ATP (or GTP, a related ... examples of motors include myosin and dynein, proteins that ... of actin or tubulin proteins. The ATP-dependent assembly of ... motor: for instance, the march of white blood cells ...
... Bork, Ph.D., Senior Bioinformatics Scientist at the European Molecular ... that they have identified a new primate-specific gene family ... of eight family members, the RGP gene cluster may ... primates from the rest of the animal kingdom. , ...
... scientists has,found the first clear evidence that the ... recognize and respond to a million,different proteins might ... apparent function is to jump around in genetic ... the genetic material, and scientists,have suspected that this ...
Cached Biology News:DNA Recombination and Repair—A New Twist to RecA Function 2Scientists document complex genomic events leading to the birth of new genes 2Scientists document complex genomic events leading to the birth of new genes 3Jumping gene helps explain immune system's abilities 2Jumping gene helps explain immune system's abilities 3
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Conferences in ... October ... OREX ), a biopharmaceutical company focused on the treatment,of obesity and ... for October 2008, which includes,six data presentations and one sponsored symposium ...
... Germany, Sept. 29 Nomad Bioscience GmbH,announces ... agreement with Bayer,Innovation GmbH and Icon Genetics ... technology platforms, including its transient expression,technology magnICON(R), ... in green plants. The agreement provides,Nomad with ...
... Cooperation with Kentucky Bioprocessing for future-oriented technology, ... 29 Bayer,Innovation GmbH and Kentucky Bioprocessing, ... at KBP,s Owensboro plant in the US ... biopharmaceuticals. Based on Bayer,s proprietary,magnICON(R) technology, plant ...
Cached Biology Technology:Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting 2Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 2Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 3Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 4